Two years Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study
2021-01-01 Pugliese, D; Privitera, G; Rogai, F; Variola, A; Viola, A; Laterza, L; Privitera, Ac; Allocca, M; Bossa, F; Cappello, M; Daperno, M; Lorenzon, G; Mazzuoli, S; Principi, M; Sablich, R; Moser, L; Ferronato, A; Traini, S; Tapete, G; Bodini, G; Di Girolamo, M; Grossi, L; Mocci, G; Ricci, C; Saibeni, S; Festa, S; Spagnuolo, R; Cortelezzi, Cc; Mocciaro, F; Rizzello, F; Armuzzi, A; Italian Group for the Study of Inflammatory Bowel Disease, (IG-IBD